The U.S. FDA has approved a new cholesterol drug called Lipfendra, made by Merck. It is the first cholesterol-lowering pill of its kind — one that works by blocking a protein called PCSK9, which normally prevents the body from clearing "bad" cholesterol from the blood. Merck announced the approval on July 16, 2026, and said the pill should be available within weeks (The Guardian). The FDA published its official approval notice the previous day on fda.gov (FDA).

Lipfendra is taken once a day and is meant to be used together with statins, the most common cholesterol medications, though in some cases it can be taken alone (Merck; The Guardian). The drug is designed to lower LDL cholesterol — the "bad" kind that can clog arteries — further than statins can manage on their own (WSJ). In late-stage clinical trials, Lipfendra reduced LDL cholesterol by up to 59% (Yahoo News). The New York Times reported that trial data show the drug can bring LDL levels down to 50 or 60 mg/dL or even lower (The Guardian).

Until now, drugs that work this way had to be given by injection. A pill form is expected to make many more patients willing to take the drug, since it removes the hurdle of self-injection that may have held back earlier versions (The Guardian).

Dr. Paja Banka, a senior clinical development leader at Merck and a pediatric cardiologist, said that seventy per cent of patients are not reaching their LDL cholesterol goal. She also reported that side effects in clinical trials were minimal, included no muscle aches, and were no different from a placebo — a dummy pill with no active ingredient (The Guardian).

The approval comes after doctors' groups recently changed their cholesterol guidelines. In March 2026, the American College of Cardiology and the American Heart Association set new LDL targets: below 100 mg/dL for patients at borderline or intermediate risk, below 70 mg/dL for high-risk patients, and below 55 mg/dL for those with atherosclerotic cardiovascular disease — a condition where plaque builds up and narrows the arteries — at very high risk (The Guardian). Heart disease remains the leading cause of death in the United States (The Guardian).

Merck set Lipfendra's list price at $10.50 per day, or more than $300 per month. The company said it expects out-of-pocket costs to be lower than the list price for many patients, though the specifics of insurance coverage and rebate deals will determine what people actually pay (The Guardian).

The broader context here is the gap between how well these drugs work in studies and how widely they get used in the real world. The earlier injectable versions of PCSK9 inhibitors cut cholesterol sharply in trials but struggled to catch on, partly because of high costs, insurance paperwork, and patients' reluctance to give themselves shots. Lipfendra's pill form removes the injection barrier. But whether that actually leads to many more prescriptions will depend on what insurers agree to cover, how much patients end up paying, and how aggressively doctors follow the new, lower cholesterol targets.

The new guidelines from March 2026 lowered the bar for what counts as healthy cholesterol, especially for the highest-risk patients, whose target is now below 55 mg/dL. If even a fraction of the patients who now fall above that target are prescribed Lipfendra, the number of potential users grows significantly. The open question for insurers and health systems is whether the cost per patient — even after discounts off the list price — is sustainable given the heart-attack and stroke prevention the drug is meant to provide.